论文部分内容阅读
目的探讨西地那非治疗新生儿持续肺动脉高压(PPHN)的临床疗效。方法选取我院2008～2011年间收治的98例持续肺动脉高压新生患儿,随机分为酚妥拉明治疗组(对照组)和西地那非治疗组(观察组),每组各49例,观察两组患儿的临床疗效。结果治疗后观察组PAMP、SaO2、PaO2、PaCO2四项指标较对照组均有显著改善(P<0.05)。治疗总有效率为89.8%,显著高于对照组的79.6%,总有效率组间差异有统计学意义(P<0.05),两组患者治疗过程中均未发生不良反应。结论西地那非治疗持续肺动脉高压新生儿临床疗效好,不良反应发生率低,操作简便,值得临床进一步推广使用。
Objective To investigate the clinical efficacy of sildenafil in the treatment of neonatal persistent pulmonary hypertension (PPHN). Methods Ninety-eight neonates with persistent pulmonary hypertension who were admitted to our hospital from 2008 to 2011 were randomly divided into two groups: control group (phentolamine) and sildenafil (observation group), 49 cases in each group, To observe the clinical efficacy of two groups of children. Results After treatment, the four indexes of PAMP, SaO2, PaO2 and PaCO2 in the observation group were significantly improved (P <0.05). The total effective rate was 89.8%, which was significantly higher than that of the control group (79.6%). The total effective rate was significantly different between the two groups (P <0.05). No adverse reactions occurred in the two groups. Conclusion Sildenafil treatment of pulmonary hypertension in neonates with good clinical efficacy, low incidence of adverse reactions, easy to operate, it is worth further clinical use.